![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
MicroStrategy
MSTR
Tesla
TSLA
MARA Holdings
MARA
Coinbase
COIN
Amazon
AMZN
US Stock MarketDetailed Quotes
NKGN NKGEN BIOTECH
- 0.787
- +0.144+22.37%
Close Dec 24 13:00 ET
27.94MMarket Cap-0.21P/E (TTM)
0.800High0.670Low604.00KVolume0.670Open0.643Pre Close450.74KTurnover3.75%Turnover RatioLossP/E (Static)35.52MShares4.06052wk High-0.40P/B12.68MFloat Cap0.20352wk Low--Dividend TTM16.11MShs Float12.880Historical High--Div YieldTTM20.22%Amplitude0.203Historical Low0.746Avg Price1Lot Size
NKGEN BIOTECH Stock Forum
Sign in to post a comment
Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
35
19
5
$NKGEN BIOTECH (NKGN.US)$
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
Monday, 2nd December at 4:05 pm
• Upon closing, the transaction would secure global IP rights for NKGen.
• NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already legal.
• NKGen proposal included up to $18 million in committed funding.
• Closing expected in 1Q 2025.
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
Monday, 2nd December at 4:05 pm
• Upon closing, the transaction would secure global IP rights for NKGen.
• NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already legal.
• NKGen proposal included up to $18 million in committed funding.
• Closing expected in 1Q 2025.
$NKGEN BIOTECH (NKGN.US)$
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech presented Phase 1/2a trial data for troculeucel in Alzheimer's Disease at the CTAD Conference. The Phase 1 trial showed that troculeucel reduces several biomarkers detectable up to 10 years before dementia symptoms. In the Phase 1/2a trial, using the highest dose of 6 billion cells, all three treated sub...
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech presented Phase 1/2a trial data for troculeucel in Alzheimer's Disease at the CTAD Conference. The Phase 1 trial showed that troculeucel reduces several biomarkers detectable up to 10 years before dementia symptoms. In the Phase 1/2a trial, using the highest dose of 6 billion cells, all three treated sub...
1
Needs to hold .3356 for a curl back up. Here are the levels to watch.
Larger Image: tradingview.com...
$NKGEN BIOTECH (NKGN.US)$
Larger Image: tradingview.com...
$NKGEN BIOTECH (NKGN.US)$
6
$Werewolf Therapeutics (HOWL.US)$ $Shoals Technologies (SHLS.US)$ $NKGEN BIOTECH (NKGN.US)$ $LogicMark (LGMK.US)$ $Aditxt (ADTX.US)$ $Aptevo Therapeutics (APVO.US)$ $VSee Health (VSEE.US)$ $Genprex (GNPX.US)$ $Spirit Airlines (SAVE.US)$ $BioVie (BIVI.US)$ $Expion360 (XPON.US)$ $GRI Bio (GRI.US)$
📊⚡️📊
📊⚡️📊
6
11
No comment yet
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Mr Brooks : Thank you. You are amazing. !!!
Trytosaveabit : As you know I’ve been waiting for this 510 clearance! I know most don’t like it! And admittedly the chart and volume are not looking good! Hehehe! But I really like, have like and continue to like MOVE! Hehehe! People don’t realize just how superior this is over the junk you can just buy on Amazon! Hehehe
Jaguar8 OP Trytosaveabit : Yes it took forever for this EvieRing to get cleared even with superior results . Glad they had it
Trytosaveabit Jaguar8 OP : Yup yup! I knew at one point you felt as I do! Not sure where you stand these days? Hehehe.
Jaguar8 OP Trytosaveabit : It was just parked on my FDA watchlist and waited forever![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
View more comments...